Matthew Lang
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Matthew Lang
Lyell Immunopharma, Inc. reported in an 8-K filed April 1, 2025 that Matthew Lang resigned as Chief Business Officer, effective April 13, 2025. The proxy statement of Lyell Immunopharma, Inc. reports total compensation of $1,869,632 for Matthew Lang in fiscal 2024, including a base salary of $516,423. Disclosed compensation is on record for 4 fiscal years.
“On March 27, 2025, Matthew Lang, J.D. notified the Company of his resignation as Chief Business Officer and from all other offices of the Company, effective April 13, 2025.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Lyell Immunopharma, Inc. (LYEL)
Proxy statement
Start not stated–2025-04-13
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Lyell Immunopharma, Inc. (LYEL) | Chief Business Officer | $516,423 | $1,869,632 |
| 2023 | Lyell Immunopharma, Inc. (LYEL) | Chief Business Officer | $250,000 | $4,008,353 |
| 2022 | Lyell Immunopharma, Inc. (LYEL) | Chief Business Officer | — | — |
| 2021 | Lyell Immunopharma, Inc. (LYEL) | Chief Business Officer | — | — |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.